Ilyas Ikramuddin, DO
Gastroenterology · Beavercreek, OHNPI 1457352940
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 24.9% of the total. Reporting peaked in 2024 at $1,464 and has fallen 97.0% since, to $44 in 2025.
Across 195 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$902
- E.r. Squibb & Sons, L.L.C.$469
- Bristol Myers Squibb$380
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$310
- Johnson & Johnson$244
- Sanofi$200
- plus $1K from 20 others
Across 59 payments — averaging $3029.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$113K
- Takeda Pharmaceuticals U.S.A., Inc.$64K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Food & beverage$3,627100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $902 |
| E.r. Squibb & Sons, L.L.C. | 4 | $469 |
| Bristol Myers Squibb | 30 | $380 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $310 |
| Johnson & Johnson | 12 | $244 |
| Sanofi | 10 | $200 |
| Madrigal Pharmaceuticals | 2 | $166 |
| Intercept Pharmaceuticals, Inc. | 3 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $138 |
| Phathom Pharmaceuticals, Inc. | 10 | $136 |
| QOL Medical, LLC | 5 | $89 |
| Pfizer | 5 | $79 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Ironwood Pharmaceuticals, Inc | 3 | $48 |
| Braintree Laboratories, Inc. | 3 | $40 |
| Ferring Pharmaceuticals Inc. | 3 | $37 |
| Organon | 3 | $36 |
| Merck | 2 | $24 |
| Romark Laboratories, LC | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| UCB, Inc. | 1 | $17 |
| Shionogi Inc | 1 | $16 |
| Evoke Pharma, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $11 |
| Micro-tech Endoscopy USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,627 in reported general payments places this provider in the 60th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $77,663 |
| VemlidyTenofovir Alafenamide | 20 | $30,565 |
| LinzessLinaclotide | 40 | $26,254 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 79 | $13,468 |
| TrulancePlecanatide | 12 | $9,736 |
| Mesalamine | 15 | $8,699 |
| Pantoprazole Sodium | 766 | $7,469 |
| Sucralfate | 30 | $4,719 |
| Mesalamine ErMesalamine | 17 | $4,665 |
| Dicyclomine Hcl | 149 | $3,031 |
| Colestipol Hcl | 49 | $2,528 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 39 | $2,311 |
| Mesalamine DrMesalamine | 16 | $2,304 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 11 | $1,715 |
| Esomeprazole Magnesium | 63 | $1,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $902 | $26,25440 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $37 | $13,46879 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $310 | $9,73612 claims |
| Braintree Laboratories, Inc.Sutab | $40 | $1,71511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Beavercreek
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Mohamed NaemWestlake$708K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
- Florian RiederCleveland$396K
- Allan PeckCincinnati$391K
- Dany RaadHighland Hills$387K
- Stanley CohenCleveland$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.